Zealand adds two Observers to the company’s Board of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand adds two Observers to the company’s Board of Directors in line with board transition plans

Copenhagen, 2014-11-10 15:06 CET (GLOBE NEWSWIRE) -- Copenhagen, 10 November 2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) announces that Dr. Martin Nicklasson and Catherine Moukheibir have been added to the company’s Board of Directors as Observers.

Dr. Martin Nicklasson has held various Executive Vice President positions at AstraZeneca Plc and been President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this, he held a number of leadership positions at Astra AB and Kabi Pharmacia AB. Martin Nicklasson is chairman of the board of Basilea AG, Orexo AB and Farma Holding A/S as well as board member in several other biotech companies in Europe. He is a certified pharmacist and holds a PhD in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Catherine Moukheibir’s particular experience lies in aligning corporate and financial strategy at various stages of a biotech company’s development, and she is currently a non-executive Board member of Creabilis Ltd. and Ablynx n.v and a member of the management board at Innate Pharma S.A. Catherine Moukheibir holds an MBA from Yale University.

For a full biography on the two new Observers, please see Zealand’s website under: www.zealandpharma.com/about/management/board-of-directors

At Zealand’s Annual General Meeting 2014, a nomination committee constituted by two shareholder representatives and two board members (see www.zealandpharma.com/about/-management/nomination-committee), was established to plan for board transitions. The appointment of Martin Nicklasson and Catherine Moukheibir as Board Observers is part of the committee's work, and it is the plan to present both for election as Independent Non-Executive Board members at Zealand’s Annual General Meeting in 2015.

The Annual General Meeting in 2015 will take place in April, and a date will be set and communicated later in 2014.

Commenting on the Board changes , Daniel J. Ellens, Chairman of the Zealand Board of Directors, said: “I am very pleased to welcome Catherine and Martin to our Board as observers, and proud that we have been able to attract such high caliber individuals to Zealand. They provide important and broad-based experience from public life science companies and are important additions to the competences on the Board as we prepare for the next steps in Zealand’s growth strategy as a maturing biotech company.”

***

For further information, please contact:

David Solomon, President and Chief Executive Officer
Tel: +45 22 20 63 00

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on cardio-metabolic diseases. The company has a broad portfolio of therapeutic products – both proprietary and partnered.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed as Lyxumia ® world-wide ex-US and in Phase III development as a single-injection combination with Lantus ® (LixiLan), both under a global license agreement with Sanofi. US regulatory filings for both products are planned for 2015 ─ summer for Lyxumia ® and as early as end 2015 for LixiLan.

Zealand is advancing a pipeline of proprietary, next-generation therapies, including danegaptide (prevention of Ischemic Reperfusion Injury) and several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com       Follow us on Twitter @ZealandPharma

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 97

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 43

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 75

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 0

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 72

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 177

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 39

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 34

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading

Top 5 Most Recently Viewed Articles

Tecsys Applauds 2026 Supply Chain Trailblazers

Updated Category News Views 26

Celebrating Supply Chain Game-Changers Diving headfirst into the world of supply chains at Tecsys's signature event, the User Conference in Nashville, showcased this year's champions who took the bull by the horns. These aren’t mere button pushers. They’re the powerhouses of healthcare and distribution, pushing operational performance to new heights. Driving Supply...

Continue Reading
Key Insights on Icelandic Salmon's Upcoming Q2 Results Webinar

Updated Category News Views 129

Exciting Presentation of Icelandic Salmon's Q2 Results Icelandic Salmon is gearing up to unveil its second quarter results for 2025. This exciting upcoming event is slated to take place on a Thursday via a Teams webinar, providing a platform for a detailed overview of the company's performance. Details of the Presentation Hosted by the esteemed CEO Bjørn Hembre alongside...

Continue Reading
TRG Screen Launches Xmon AI Assist for Enhanced Data Insights

Updated Category News Views 225

Revolutionizing Data Management with AI Technology In today's fast-paced financial landscape, organizations are constantly seeking tools that streamline operations and enhance decision-making capabilities. TRG Screen has risen to the occasion with the introduction of Xmon AI Assist, a cutting-edge innovation designed to transform how financial institutions manage their...

Continue Reading
Crypto Analyst Raoul Pal Discusses the Current Banana Zone Trends

Updated Category News Views 379

Raoul Pal’s Insights on the Current Crypto Market U.Today - Raoul Pal, the founder and CEO of Real Vision, is widely recognized for his expertise in cryptocurrency and investing. Recently, he took to the social media platform X (formerly known as Twitter) to engage with his followers about the prevailing conditions in the crypto market and the future outlook for...

Continue Reading
Investing $1000 in Gold Fields: A 5-Year Growth Journey

Updated Category News Views 230

The Incredible Return on Gold Fields Investment Gold Fields (NYSE: GFI) has remarkably outperformed the market in the past five years, showcasing an annualized return of 27.98%—a substantial difference over standard investment returns. With a current market capitalization of $38.14 billion, Gold Fields stands out as a worthwhile investment opportunity. What If You...

Continue Reading